MyFinsight
Home
Blog
About
Contact
ikt: the balance sheet
Download
Download image
Prepaid expenses and
other current assets
$618,783
Deferred offering costs
$385,062
Prepaid research and
development
$210,566
Marketable securities
$39,052,511
Cash and cash
equivalents
$38,269,706
Other assets
$57,913
Prepaid research and
development, noncurrent
$1,000,000
Total current assets
$78,536,628
Total assets
$79,594,541
Total liabilities and
stockholders' equity
$79,594,541
Total stockholders'
equity
$72,898,298
Total liabilities
$6,696,243
Accumulated deficit
-$129,945,149
Accumulated other
comprehensive loss
-$4,189
Additional paid-in capital
$202,772,828
Total current
liabilities
$6,696,243
Common stock, 0.001 par
value 500,000,000 and...
$74,808
Contingent consideration
liability
$2,419,332
Accrued expenses and
other current...
$3,656,383
Accounts payable
$620,528
Back
Back
Balance Sheet
source: myfinsight.com
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)